Deutsche Bank analyst Emmanuel Papadakis raised the firm’s price target on Novartis (NVS) to CHF 115 from CHF 110 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Novartis Gains FDA Approval for Vanrafia in IgA Nephropathy
- Novartis gets FDA accelerated approval for Vanrafia
- Needham healthcare analysts hold analyst/industry conference call
- FDA Approves Novartis’ Pluvicto for Early Use in Prostate Cancer Treatment
- FDA approves Novartis radioligand therapy Pluvicto for earlier use in mCRPC